{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:01:13Z","timestamp":1789236073310,"version":"build-2803163510"},"reference-count":134,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["81573277"],"award-info":[{"award-number":["81573277"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["81622042"],"award-info":[{"award-number":["81622042"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["81773567"],"award-info":[{"award-number":["81773567"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Proteolysis targeting chimeras (PROTAC) represents a new type of small molecule induced protein degradation technology that has emerged in recent years. PROTAC uses bifunctional small molecules to induce ubiquitination of target proteins and utilizes intracellular proteasomes for chemical knockdown. It complements the gene editing and RNA interference for protein knockdown. Compared with small molecule inhibitors, PROTAC has shown great advantages in overcoming tumor resistance, affecting the non-enzymatic function of target proteins, degrading undruggable targets, and providing new rapid and reversible chemical knockout tools. At the same time, its challenges and problems also need to be resolved as a fast-developing newchemical biology technology.<\/jats:p>","DOI":"10.3389\/fcell.2021.685106","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T05:22:48Z","timestamp":1624425768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation"],"prefix":"10.3389","volume":"9","author":[{"given":"Ming","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41589-020-00652-y","article-title":"PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase.","volume":"16","author":"Adhikari","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1021\/acs.jmedchem.7b01306","article-title":"Current insights of BRAF inhibitors in cancer.","volume":"61","author":"Agianian","year":"2018","journal-title":"J. Med. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/mmbr.67.4.657-685.2003","article-title":"RNA interference: biology, mechanism, and applications.","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41467-021-21159-7","article-title":"Mutant-selective degradation by BRAF-targeting PROTACs.","volume":"12","author":"Alabi","year":"2021","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bbamcr.2013.06.031","article-title":"Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system.","volume":"1843","author":"Amm","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"B6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s13238-018-0602-z","article-title":"Developing potent PROTACs tools for selective degradation of HDAC6 protein.","volume":"10","author":"An","year":"2019","journal-title":"Protein Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/07391102.2007.10507153","article-title":"Computational approach for the design of AP1867 analogs: aiming at new synthetic routes for potential immunosuppressant agents.","volume":"25","author":"Andrade","year":"2007","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B8","doi-asserted-by":"publisher","first-page":"10420","DOI":"10.1021\/ja00075a092","article-title":"Structure-based design of an acyclic ligand that bridges FKBP12 and Calcineurin.","volume":"115","author":"Andrus","year":"1993","journal-title":"J. Am. Chem. Soc"},{"key":"B9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo.","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077639","article-title":"PD-0332991, a CDK4\/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma.","volume":"8","author":"Barton","year":"2013","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1021\/jm301098e","article-title":"Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.","volume":"55","author":"Bergman","year":"2012","journal-title":"J. Med. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/34657","article-title":"Induction of epithelial tubules by growth factor HGF depends on the STAT pathway.","volume":"391","author":"Boccaccio","year":"1998","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved for BRAF-mutant cancer.","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs.","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/embj.201386399","article-title":"FAK dimerization controls its kinase-dependent functions at focal adhesions.","volume":"33","author":"Brami-Cherrier","year":"2014","journal-title":"EMBO J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.chembiol.2018.11.006","article-title":"Homolog-selective degradation as a strategy to probe the function of CDK6 in AML.","volume":"26","author":"Brand","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"8446","DOI":"10.1002\/anie.201202134","article-title":"Light-controlled tools.","volume":"51","author":"Brieke","year":"2012","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ccr.2013.05.005","article-title":"Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.","volume":"24","author":"Brockmann","year":"2013","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S Ibrutinib-resistance mutation in bruton\u2019s tyrosine kinase using PROTAC-mediated degradation.","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery.","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"923","DOI":"10.4155\/fmc-2018-0304","article-title":"KRAS(G12C) inhibitors on the horizon.","volume":"11","author":"Cagir","year":"2019","journal-title":"Future Med. Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.","volume":"29","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov."},{"key":"B24","doi-asserted-by":"publisher","first-page":"15051","DOI":"10.1073\/pnas.0910258107","article-title":"Dysregulation of the mevalonate pathway promotes transformation.","volume":"107","author":"Clendening","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM199912093412415","article-title":"Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.","volume":"341","author":"Cohen","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"17019","DOI":"10.1021\/jacs.8b08008","article-title":"Addressing kinase-independent functions of Fak via PROTAC-mediated degradation.","volume":"140","author":"Cromm","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nm.4107","article-title":"A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.","volume":"22","author":"Dauch","year":"2016","journal-title":"Nat. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1182\/blood-2018-07-862953","article-title":"Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.","volume":"133","author":"Dobrovolsky","year":"2019","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.144813","article-title":"Challenges of in vitro genome editing with CRISPR\/Cas9 and possible solutions: a review.","volume":"753","author":"Ebrahimi","year":"2020","journal-title":"Gene"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.126877","article-title":"Design, synthesis and biological evaluation of proteolysis targeting chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.","volume":"30","author":"Figueroa","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8657","DOI":"10.1021\/jm5011258","article-title":"Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities.","volume":"57","author":"Galdeano","year":"2014","journal-title":"J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: opportunities and challenges.","volume":"11","author":"Gao","year":"","journal-title":"ACS Med. Chem. Lett."},{"key":"B34","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13238-020-00732-8","article-title":"FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice.","volume":"11","author":"Gao","year":"","journal-title":"Protein Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1021\/acsmedchemlett.9b00372","article-title":"Design, synthesis, and evaluation of highly potent FAK-targeting PROTACs.","volume":"11","author":"Gao","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"B36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nchembio.1534","article-title":"How to control proteins with light in living systems.","volume":"10","author":"Gautier","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients.","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1021\/acs.jmedchem.9b02083","article-title":"Discovery of Selective Small Molecule Degraders of BRAF-V600E.","volume":"63","author":"Han","year":"2020","journal-title":"J. Med. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1039\/c5cs00118h","article-title":"Wavelength-selective cleavage of photoprotecting groups: strategies and applications in dynamic systems.","volume":"44","author":"Hansen","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1158\/1541-7786","article-title":"The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration.","volume":"11","author":"Hartman","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/mc.20790","article-title":"Focal adhesion kinase is required for KSHV vGPCR signaling.","volume":"51","author":"He","year":"2012","journal-title":"Mol. Carcinog."},{"key":"B42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"9925","DOI":"10.1021\/ja00075a008","article-title":"Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal-structures of their complexes with FKBP12.","volume":"115","author":"Holt","year":"1993","journal-title":"J. Am. Chem. Soc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","article-title":"A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader.","volume":"25","author":"Huang","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s0092-8674(00)80555-3","article-title":"Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12.","volume":"96","author":"Huse","year":"1999","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1021\/ja100691p","article-title":"Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.","volume":"132","author":"Itoh","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"B47","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1002\/anie.201901336","article-title":"Development of dual and selective degraders of Cyclin-Dependent Kinases 4 and 6.","volume":"58","author":"Jiang","year":"2019","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B48","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1021\/acs.jmedchem.9b02058","article-title":"Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown.","volume":"63","author":"Jin","year":"2020","journal-title":"J. Med. Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nrc.2017.79","article-title":"New perspectives for targeting RAF kinase in human cancer.","volume":"17","author":"Karoulia","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM199912093412415","article-title":"Drugging an undruggable pocket on KRAS.","volume":"341","author":"Kessler","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1021\/ol027454g","article-title":"Sequentially photocleavable protecting groups in solid-phase synthesis.","volume":"5","author":"Kessler","year":"2003","journal-title":"Org. Lett."},{"key":"B52","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.1039\/d0cc00523a","article-title":"A caged E3 ligase ligand for PROTAC-mediated protein degradation with light.","volume":"56","author":"Kounde","year":"2020","journal-title":"Chem. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.tips.2014.08.001","article-title":"Drugging the HDAC6-HSP90 interplay in malignant cells.","volume":"35","author":"Kr\u00e4mer","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm.","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B55","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL.","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B56","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1021\/acs.jmedchem.0c00339","article-title":"Degradation versus inhibition: development of proteolysis-targeting chimeras for overcoming statin-induced compensatory upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase.","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway.","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.3392","article-title":"Tumor adaptation and resistance to RAF inhibitors.","volume":"19","author":"Lito","year":"2013","journal-title":"Nat. Med."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay5154","article-title":"Light-induced control of protein destruction by opto-PROTAC.","volume":"6","author":"Liu","year":"2020","journal-title":"Sci. Adv."},{"key":"B61","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1039\/c5cs00911a","article-title":"Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.","volume":"45","author":"Lu","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1016\/j.bmcl.2015.07.006","article-title":"Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.","volume":"25","author":"Lu","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B63","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nn.3078","article-title":"A toolbox of Cre-dependent optogenetic transgenic mice for light-induced activation and silencing.","volume":"15","author":"Madisen","year":"2012","journal-title":"Nat. Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrc1526","article-title":"Aurora-A - a guardian of poles.","volume":"5","author":"Marumoto","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/s1074-7613(01)00101-7","article-title":"STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation.","volume":"14","author":"McLemore","year":"2001","journal-title":"Immunity"},{"key":"B66","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.tcm.2009.10.003","article-title":"The Role of HMGCR alternative splicing in statin efficacy.","volume":"19","author":"Medina","year":"2009","journal-title":"Trends Cardiovasc. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature02872","article-title":"Revealing the world of RNA interference.","volume":"431","author":"Mello","year":"2004","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nchembio.2140","article-title":"Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.","volume":"12","author":"Miyake","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","article-title":"The dTAG system for immediate and target-specific protein degradation.","volume":"14","author":"Nabet","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1021\/jacs.9b12718","article-title":"Optical control of small molecule-induced protein degradation.","volume":"142","author":"Naro","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.259","article-title":"ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer.","volume":"37","author":"Neklesa","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3109\/10428194.2015.1030641","article-title":"Phase 1\/2 study of cyclin-dependent kinase (CDK)4\/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma.","volume":"56","author":"Niesvizky","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"B73","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/35048096","article-title":"Mitotic kinases as regulators of cell division and its checkpoints.","volume":"2","author":"Nigg","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1021\/acschembio.6b01068","article-title":"Proteolysis-targeting chimeras: induced protein degradation as a therapeutic strategy.","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ccr.2008.12.005","article-title":"Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.","volume":"15","author":"Otto","year":"2009","journal-title":"Cancer Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy.","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase.","volume":"2","author":"Pan","year":"2007","journal-title":"Chem. Med. Chem."},{"key":"B78","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1158\/0008-5472.CAN-05-3832","article-title":"Levels of HdmX expression dictate the sensitivity of normal and transformed cells to nutlin-3.","volume":"66","author":"Patton","year":"2006","journal-title":"Cancer Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1021\/acscentsci.9b00713","article-title":"Reversible spatiotemporal control of induced protein degradation by bistable PhotoPROTACs.","volume":"5","author":"Pfaff","year":"2019","journal-title":"ACS Cent. Sci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","article-title":"The role of new tyrosine kinase inhibitors in chronic myeloid leukemia.","volume":"22","author":"Pophali","year":"2016","journal-title":"Cancer J."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1021\/acs.jmedchem.8b01826","article-title":"Highly selective PTK2 proteolysis targeting chimeras to probe Focal Adhesion Kinase scaffolding functions.","volume":"62","author":"Popow","year":"2019","journal-title":"J. Med. Chem."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/s41589-020-0609-7","article-title":"Functional characterization of a PROTAC directed against BRAF mutant V600E.","volume":"16","author":"Posternak","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web.","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay5064","article-title":"PHOTACs enable optical control of protein degradation.","volume":"6","author":"Reynders","year":"2020","journal-title":"Sci. Adv."},{"key":"B85","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1083\/jcb.201103008","article-title":"The Ras protein superfamily: evolutionary tree and role of conserved amino acids.","volume":"196","author":"Rojas","year":"2012","journal-title":"J. Cell Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation.","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B87","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges.","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"B88","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR signaling in growth, metabolism, and disease.","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics.","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/ncb1626","article-title":"Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2\/3 complex.","volume":"9","author":"Serrels","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1021\/acsmedchemlett.7b00247","article-title":"Targeting the allosteric site of oncoprotein BCR-ABL as an alternative strategy for effective target protein degradation.","volume":"8","author":"Shimokawa","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-8-7","article-title":"HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?","volume":"8","author":"Sim\u00f5es-Pires","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"B93","doi-asserted-by":"publisher","first-page":"11872","DOI":"10.1021\/la802052u","article-title":"Photoresponsive surfaces with two independent wavelength-selective functional levels.","volume":"24","author":"Stegmaier","year":"2008","journal-title":"Langmuir"},{"key":"B94","doi-asserted-by":"publisher","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","article-title":"Potent and preferential degradation of CDK6 via proteolysis targeting chimera degraders.","volume":"62","author":"Su","year":"2019","journal-title":"J. Med. Chem."},{"key":"B95","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry.","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Target Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1021\/acs.biochem.9b00848","article-title":"PROTACs as potential therapeutic agents for cancer drug resistance.","volume":"59","author":"Sun","year":"2020","journal-title":"Biochemistry"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-018-0079-1","article-title":"A chemical approach for global protein knockdown from mice to non-human primates.","volume":"5","author":"Sun","year":"2018","journal-title":"Cell Discov."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41375-019-0440-x","article-title":"Degradation of Bruton\u2019s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.","volume":"33","author":"Sun","year":"2019","journal-title":"Leukemia"},{"key":"B99","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.1021\/cr300179f","article-title":"Reversible photocontrol of biological systems by the incorporation of molecular photoswitches.","volume":"113","author":"Szymanski","year":"2013","journal-title":"Chem. Rev."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.1382.1382","article-title":"The MDM2 antagonist nutlin-3 is lethal to mantle cell lymphoma with wild type p53.","volume":"110","author":"Tabe","year":"2007","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1021\/acs.jmedchem.8b01469","article-title":"Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update.","volume":"62","author":"Tadesse","year":"2019","journal-title":"J. Med. Chem."},{"key":"B103","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1080\/15384101.2015.1084445","article-title":"Targeting CDK6 in cancer: state of the art and new insights.","volume":"14","author":"Tadesse","year":"2015","journal-title":"Cell Cycle"},{"key":"B104","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1158\/0008-5472.CAN-17-1240","article-title":"FBW7 loss promotes chromosomal instability and tumorigenesis via cyclin E1\/CDK2-mediated phosphorylation of CENP-A.","volume":"77","author":"Takada","year":"2017","journal-title":"Cancer Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1073\/pnas.94.8.3801","article-title":"Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality.","volume":"94","author":"Takeda","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1021\/acs.jmedchem.8b01508","article-title":"Photoactivatable prodrug of doxazolidine targeting exosomes.","volume":"62","author":"Tamura","year":"2019","journal-title":"J. Med. Chem."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/S0960-894X(01)80992-6","article-title":"The affinity of the excised binding domain of FK-506 for the immunophilin FKBP12.","volume":"3","author":"Teague","year":"1993","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACS: new approaches to protein degradation.","volume":"55","author":"Toure","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B110","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/ncb2242","article-title":"A kinase-independent role for Aurora A in the assembly of mitotic spindle microtubules in Caenorhabditis elegans embryos.","volume":"13","author":"Toya","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","article-title":"The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif."},{"key":"B112","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41589-021-00742-5","article-title":"Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.","volume":"17","author":"Wang","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma.","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1021\/jm980252z","article-title":"Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12.","volume":"42","author":"Wiedeman","year":"1999","journal-title":"J. Med. Chem."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation.","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"B116","doi-asserted-by":"publisher","first-page":"7042","DOI":"10.1021\/acs.jmedchem.9b00516","article-title":"Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity.","volume":"62","author":"Wu","year":"2019","journal-title":"J. Med. Chem."},{"key":"B117","doi-asserted-by":"publisher","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-induced protein degradation with photocaged PROTACs.","volume":"141","author":"Xue","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/onc.2016.379","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence.","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"key":"B119","doi-asserted-by":"publisher","first-page":"14848","DOI":"10.1039\/c9cc08509b","article-title":"Plasticity in designing PROTACs for selective and potent degradation of HDAC6.","volume":"55","author":"Yang","year":"2019","journal-title":"Chem. Commun."},{"key":"B120","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review.","volume":"93","author":"Yang","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.bmcl.2018.05.057","article-title":"Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.","volume":"28","author":"Yang","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B122","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1021\/acsmedchemlett.0c00046","article-title":"Development of selective histone deacetylase 6(HDAC6) degraders recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase.","volume":"11","author":"Yang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"B123","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.1021\/acs.jmedchem.0c00967","article-title":"A global PROTAC toolbox for degrading BCR-ABL overcomes drug-resistant mutants and adverse effects.","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med. Chem."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1182\/blood-2017-10-813139","article-title":"Ubiquitin-dependent degradation of CDK2 drives the therapeutic diferentiation of AML by targeting PRDX2.","volume":"131","author":"Ying","year":"2018","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1183\/09031936.00149011","article-title":"Atorvastatin in Pulmonary Arterial Hypertension (APATH) study.","volume":"40","author":"Zeng","year":"2012","journal-title":"Eur. Respir. J."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective small molecule induced degradation of the BET bromodomain protein BRD4.","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nchembio.2456","article-title":"Optogenetic control of kinetochore function.","volume":"13","author":"Zhang","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.molcel.2007.05.033","article-title":"HDAC6 modulates cell motility by altering the acetylation level of cortactin.","volume":"27","author":"Zhang","year":"2007","journal-title":"Mol. Cell."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1039\/c9cc00163h","article-title":"PROTACs suppression of CDK4\/6, crucial kinases for cell cycle regulation in cancer.","volume":"55","author":"Zhao","year":"2019","journal-title":"Chem. Commun."},{"key":"B130","doi-asserted-by":"publisher","first-page":"9281","DOI":"10.1021\/acs.jmedchem.9b01264","article-title":"Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase.","volume":"62","author":"Zhao","year":"2019","journal-title":"J. Med. Chem."},{"key":"B131","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1039\/c8cc07813k","article-title":"Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule.","volume":"55","author":"Zhao","year":"2019","journal-title":"Chem. Commun."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10180","article-title":"Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype.","volume":"7","author":"Zheng","year":"2016","journal-title":"Nat. Commun."},{"key":"B133","doi-asserted-by":"publisher","first-page":"E7285","DOI":"10.1073\/pnas.1803662115","article-title":"Delineating the role of cooperativity in the design of potent PROTACs for BTK.","volume":"115","author":"Zorba","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.SA."},{"key":"B134","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development.","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem. Funct."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.685106\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T05:22:51Z","timestamp":1624425771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.685106\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":134,"alternative-id":["10.3389\/fcell.2021.685106"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2021.685106","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"article-number":"685106"}}